Free Access
Med Sci (Paris)
Volume 34, October 2018
Cancer biomarkers
Page(s) 99 - 104
Published online 07 November 2018
  1. Haggar FA Boushey RP Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 2009 ; 22 : 191–197. [CrossRef] [Google Scholar]
  2. Arnold M Sierra MS Laversanne M Soerjomataram I Jemal A Bray F Global patterns and trends in colorectal cancer incidence and mortality. Gut 2017 ; 66 : 683–691. [CrossRef] [PubMed] [Google Scholar]
  3. Gonzalez M Robert JH Halkic N Mentha G Roth A Perneger T Ris HB Gervaz P Survival after lung metastasectomy in colorectal cancer patients with previously resected liver metastases. World J Surg 2012 ; 36 : 386–391. [CrossRef] [PubMed] [Google Scholar]
  4. Beck JT Ismail A Tolomeo C Targeting the phosphatidylinositol 3-kinase (pi3k)/akt/mammalian target of rapamycin (mtor) pathway: An emerging treatment strategy for squamous cell lung carcinoma. Cancer Treat Rev 2014 ; 40 : 980–989. [CrossRef] [PubMed] [Google Scholar]
  5. Papadimitrakopoulou V. Development of pi3k/akt/mtor pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. J Thorac Oncol 2012 ; 7 : 1315–1326. [CrossRef] [Google Scholar]
  6. Huang J Manning BD The tsc1-tsc2 complex: A molecular switchboard controlling cell growth. Biochem J 2008 ; 412 : 179–190. [CrossRef] [PubMed] [Google Scholar]
  7. Hoogeveen-Westerveld M van Unen L van den Ouweland A Halley D Hoogeveen A Nellist M The tsc1-tsc2 complex consists of multiple tsc1 and tsc2 subunits. BMC Biochem 2012 ; 13 : 18. [CrossRef] [PubMed] [Google Scholar]
  8. Li Y Inoki K Vikis H Guan KL Measurements of tsc2 gap activity toward rheb. Methods Enzymol 2006 ; 407 : 46–54. [CrossRef] [PubMed] [Google Scholar]
  9. Li Y Inoki K Guan KL Biochemical and functional characterizations of small gtpase rheb and tsc2 gap activity. Mol Cell Biol 2004 ; 24 : 7965–7975. [CrossRef] [PubMed] [Google Scholar]
  10. Inoki K Li Y Xu T Guan KL Rheb gtpase is a direct target of tsc2 gap activity and regulates mtor signaling. Genes Dev 2003 ; 17 : 1829–1834. [CrossRef] [PubMed] [Google Scholar]
  11. Parmar N Tamanoi F Rheb g-proteins and the activation of mtorc1. Enzymes 2010 ; 27 : 39–56. [CrossRef] [Google Scholar]
  12. Sato T Nakashima A Guo L Tamanoi F Specific activation of mtorc1 by rheb g-protein in vitro involves enhanced recruitment of its substrate protein. J Biol Chem 2009 ; 284 : 12783–12791. [CrossRef] [PubMed] [Google Scholar]
  13. Lee JT Lehmann BD Terrian DM Chappell WH Stivala F Libra M Martelli AM Steelman LS McCubrey JA Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 2008 ; 7 : 1745–1762. [CrossRef] [PubMed] [Google Scholar]
  14. Chang F Lee JT Navolanic PM Steelman LS Shelton JG Blalock WL Franklin RA McCubrey JA Involvement of pi3k/akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: A target for cancer chemotherapy. Leukemia 2003 ; 17 : 590–603. [CrossRef] [PubMed] [Google Scholar]
  15. Miled N Yan Y Hon WC Perisic O Zvelebil M Inbar Y Schneidman-Duhovny D Wolfson HJ Backer JM Williams RL Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 2007 ; 317 : 239–242. [CrossRef] [Google Scholar]
  16. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the pten tumour suppressor. Nat Rev Mol Cell Biol 2012;13:283–296. [CrossRef] [PubMed] [Google Scholar]
  17. Huang WC Hung MC Beyond nf-kappab activation: Nuclear functions of ikappab kinase alpha. J Biomed Sci 2013 ; 20 : 3. [CrossRef] [PubMed] [Google Scholar]
  18. Ruvolo PP Deng X May WS Phosphorylation of bcl2 and regulation of apoptosis. Leukemia 2001 ; 15 : 515–522. [CrossRef] [PubMed] [Google Scholar]
  19. Carnero A Blanco-Aparicio C Renner O Link W Leal JF The pten/pi3k/akt signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 2008 ; 8 : 187–198. [CrossRef] [PubMed] [Google Scholar]
  20. McNamara CR Degterev A Small-molecule inhibitors of the pi3k signaling network. Future Med Chem 2011 ; 3 : 549–565. [CrossRef] [PubMed] [Google Scholar]
  21. Geuna E Milani A Martinello R Aversa C Valabrega G Scaltriti M Montemurro F Buparlisib, an oral pan-pi3k inhibitor for the treatment of breast cancer. Expert Opin Investig Drugs 2015 ; 24 : 421–431. [CrossRef] [PubMed] [Google Scholar]
  22. Malkomes P Lunger I Luetticke A Oppermann E Haetscher N Serve H Holzer K Bechstein WO Rieger MA Selective akt inhibition by mk-2206 represses colorectal cancer-initiating stem cells. Ann Surg Oncol 2016 ; 23 : 2849–2857. [CrossRef] [PubMed] [Google Scholar]
  23. Hurez V Dao V Liu A Pandeswara S Gelfond J Sun L Bergman M Orihuela CJ Galvan V Padron A Drerup J Liu Y Hasty P Sharp ZD Curiel TJ Chronic mtor inhibition in mice with rapamycin alters t, b, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice. Aging Cell 2015 ; 14 : 945–956. [CrossRef] [PubMed] [Google Scholar]
  24. Wang H Zhang L Yang X Jin Y Pei S Zhang D Zhang H Zhou B Zhang Y Lin D Puma mediates the combinational therapy of 5-fu and nvp-bez235 in colon cancer. Oncotarget 2015 ; 6 : 14385–14398. [PubMed] [Google Scholar]
  25. Zhu L Ding X Zhu X Meng S Wang J Zhou H Duan Q Tao J Schifferli DM Zhu G Biphasic activation of pi3k/akt and mapk/erk1/2 signaling pathways in bovine herpesvirus type 1 infection of mdbk cells. Vet Res 2011 ; 42 : 57. [CrossRef] [PubMed] [Google Scholar]
  26. Martelli AM Evangelisti C Follo MY Ramazzotti G Fini M Giardino R Manzoli L McCubrey JA Cocco L Targeting the phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin signaling network in cancer stem cells. Curr Med Chem 2011 ; 18 : 2715–2726. [CrossRef] [PubMed] [Google Scholar]
  27. Mijatovic T Mahieu T Bruyere C De Neve N Dewelle J Simon G Dehoux MJ van der Aar E Haibe-Kains B Bontempi G Decaestecker C Van Quaquebeke E Darro F Kiss R Unbs5162, a novel naphthalimide that decreases cxcl chemokine expression in experimental prostate cancers. Neoplasia 2008 ; 10 : 573–586. [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.